Qiagen and CytoPathfinder Combines Technologies in RNAi Screening
News May 24, 2006
Qiagen and CytoPathfinder have announced the formation of a strategic partnership between the two companies to combine their technologies in developing advanced tools for high-throughput RNAi screening.
CytoPathfinder has developed a Transfection Microarray technology (TMA) which allows high-throughput siRNA screening on a microarray chip.
Both companies have agreed to combine product knowledge and technology platforms to develop new-generation tools for high-throughput RNAi screening.
These developments have made high-throughput RNAi accessible to both pharmaceutical companies and academic researchers.
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019
10th International Tissue Repair and Regeneration Congress
Jun 13 - Jun 14, 2019
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019